Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

SK Bioscience Co Stock

302440.KS
KR7302440003

Price

53,600.00
Today +/-
+0
Today %
+0 %
P

SK Bioscience Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SK Bioscience Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SK Bioscience Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SK Bioscience Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SK Bioscience Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SK Bioscience Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SK Bioscience Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SK Bioscience Co’s growth potential.

SK Bioscience Co Revenue, EBIT and net profit per share

DateSK Bioscience Co RevenueSK Bioscience Co EBITSK Bioscience Co Net Income
2026e347.73 B undefined-19.05 B undefined-14.11 B undefined
2025e314.87 B undefined-56.03 B undefined-31.61 B undefined
2024e223.63 B undefined-68.07 B undefined-47.48 B undefined
2023369.51 B undefined-11.99 B undefined22.32 B undefined
2022456.73 B undefined115.01 B undefined122.45 B undefined
2021929 B undefined474.22 B undefined355.14 B undefined
2020225.61 B undefined37.71 B undefined32.89 B undefined
2019183.94 B undefined22.8 B undefined14.68 B undefined
201899.4 B undefined26.44 B undefined8.93 B undefined

SK Bioscience Co Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2018201920202021202220232024e2025e2026e
99.4183.94225.61929456.73369.51223.63314.87347.73
-85.0422.66311.77-50.84-19.10-39.4840.8010.44
50.7542.3342.2661.3952.4638.50---
50.4577.8695.34570.28239.61142.24000
26.4422.837.71474.22115.01-11.99-68.07-56.03-19.05
26.5912.3916.7151.0525.18-3.24-30.44-17.80-5.48
8.9314.6832.89355.14122.4522.32-47.48-31.61-14.11
-64.30124.09979.78-65.52-81.77-312.76-33.42-55.38
61616273.8377.0277.01000
---------
Details

Keystats

ⓘ

Revenue and Growth

The SK Bioscience Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SK Bioscience Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SK Bioscience Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SK Bioscience Co's financial health and stability.

Assets

SK Bioscience Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SK Bioscience Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SK Bioscience Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SK Bioscience Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20182019202020212022
8.9314.6832.89355.14122.45
6.614.5416.5318.7827.24
00000
-18.5-4.4362.232.06-310.87
17.8711.188.61130.6236.22
2.454.514.063.412.68
0.077.580.258.99104.21
14.935.97120.22536.59-124.96
-6,310-23,968-10,198-44,469-76,489
-17.64-2.65-108.09-1,421.94272.65
-11.3321.32-97.9-1,377.47349.14
00000
-10,000-23,435-1,237-24,247-22,485
10.9800983.262.62
0.84-23.44-1.54958.38-19.87
-144.00--301.00-628.00-
00000
-1.99.8910.5973.06127.26
8,59312,005110,026492,124.12-201,447.73
00000

SK Bioscience Co stock margins

The SK Bioscience Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SK Bioscience Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SK Bioscience Co.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SK Bioscience Co's sales revenue. A higher gross margin percentage indicates that the SK Bioscience Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SK Bioscience Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SK Bioscience Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SK Bioscience Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SK Bioscience Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SK Bioscience Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SK Bioscience Co Margin History

SK Bioscience Co Gross marginSK Bioscience Co Profit marginSK Bioscience Co EBIT marginSK Bioscience Co Profit margin
2026e38.5 %-5.48 %-4.06 %
2025e38.5 %-17.8 %-10.04 %
2024e38.5 %-30.44 %-21.23 %
202338.5 %-3.24 %6.04 %
202252.46 %25.18 %26.81 %
202161.39 %51.05 %38.23 %
202042.26 %16.71 %14.58 %
201942.33 %12.39 %7.98 %
201850.75 %26.59 %8.99 %

SK Bioscience Co Stock Sales Revenue, EBIT, Earnings per Share

The SK Bioscience Co earnings per share therefore indicates how much revenue SK Bioscience Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SK Bioscience Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SK Bioscience Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SK Bioscience Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SK Bioscience Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SK Bioscience Co Revenue, EBIT and net profit per share

DateSK Bioscience Co Sales per ShareSK Bioscience Co EBIT per shareSK Bioscience Co Earnings per Share
2026e4,526.13 undefined0 undefined-183.61 undefined
2025e4,098.44 undefined0 undefined-411.46 undefined
2024e2,910.75 undefined0 undefined-618.03 undefined
20234,797.92 undefined-155.66 undefined289.79 undefined
20225,929.85 undefined1,493.27 undefined1,589.84 undefined
202112,582.62 undefined6,422.95 undefined4,810.09 undefined
20203,638.89 undefined608.23 undefined530.48 undefined
20193,015.38 undefined373.72 undefined240.61 undefined
20181,629.56 undefined433.38 undefined146.44 undefined

SK Bioscience Co business model

SK Bioscience Co is one of the most popular companies on Eulerpool.com.

SK Bioscience Co valuation based on historical P/E ratio, EBIT, and P/S ratio.

SK Bioscience Co shares outstanding

The number of shares was SK Bioscience Co in 2023 — This indicates how many shares 77.014 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SK Bioscience Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SK Bioscience Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SK Bioscience Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SK Bioscience Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for SK Bioscience Co.

SK Bioscience Co Earnings Surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-241.21 -179  (25.79 %)2024 Q1
9/30/2023441.67 630  (42.64 %)2023 Q3
6/30/2023-19.35 -208  (-974.9 %)2023 Q2
3/31/2023192.68 -186  (-196.53 %)2023 Q1
12/31/2022497.83 360  (-27.69 %)2022 Q4
9/30/2022270.94 270  (-0.35 %)2022 Q3
6/30/2022837.03 599  (-28.44 %)2022 Q2
3/31/20221,342.3 361.04  (-73.1 %)2022 Q1
12/31/20212,605.19 2,387.15  (-8.37 %)2021 Q4
1

Eulerpool ESG Scorecard© for the SK Bioscience Co stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

86

👫 Social

61

🏛️ Governance

77

Environment

Scope 1 - Direct Emissions
4,870
Scope 2 - Indirect emissions from purchased energy
12,059
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
16,929
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees36.842
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

Kontaktformular an uns. The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

SK Bioscience Co Stock Shareholders

%
Name
Stocks
Change
Date
67.76 % SK Chemicals Co., Ltd.52,059,724-290,27612/28/2023
0.90 % The Vanguard Group, Inc.689,268573/31/2024
0.81 % BlackRock Institutional Trust Company, N.A.620,87716,9063/31/2024
0.65 % SK Bioscience Co., Ltd. Employees501,027-19,0329/30/2023
0.38 % Samsung Asset Management Co., Ltd.288,803-8842/29/2024
0.28 % BlackRock Advisors (UK) Limited217,8461,7413/31/2024
0.28 % Mirae Asset Global Investments Co., Ltd.211,598-2,1952/29/2024
0.18 % Norges Bank Investment Management (NBIM)140,205-221,08212/31/2023
0.16 % Geode Capital Management, L.L.C.121,5002,9022/29/2024
0.08 % Northern Trust Global Investments Limited59,4251,5262/29/2024
1
2
3
4
5
...
10

SK Bioscience Co Executives and Management Board

Mr. Hun Kim55
SK Bioscience Co Director (since 2022)
Compensation 7.25 B
Mr. Jae Yong Ahn54
SK Bioscience Co President, Chief Executive Officer, Director (since 2022)
Compensation 7.24 B
Mr. Jae Seon Hwang45
SK Bioscience Co Chief Information Security Officer
Mr. Jong Su Park52
SK Bioscience Co Chief Privacy Officer
Mr. Jae Hyeon Ahn57
SK Bioscience Co Other Non-Executive Director
1
2

SK Bioscience Co stock: Frequently Asked Questions

What is the P/E ratio of SK Bioscience Co 2024?

The SK Bioscience Co P/E ratio is -86.94.

What is the P/S ratio of SK Bioscience Co 2024?

The SK Bioscience Co P/S ratio is 18.46.

What is the AlleAktien quality score of SK Bioscience Co?

The AlleAktien quality score for SK Bioscience Co is 1/10.

What is the revenue of SK Bioscience Co 2024?

The expected SK Bioscience Co revenue is 223.63 B KRW.

How high is the profit of SK Bioscience Co 2024?

The expected SK Bioscience Co profit is -47.48 B KRW.

What is the business model of SK Bioscience Co

No history available for SK Bioscience Co.

What is the SK Bioscience Co dividend?

SK Bioscience Co pays a dividend of 0 KRW distributed over payouts per year.

How often does SK Bioscience Co pay dividends?

The dividend cannot currently be calculated for SK Bioscience Co or the company does not pay out a dividend.

What is the SK Bioscience Co ISIN?

The ISIN of SK Bioscience Co is KR7302440003.

What is the SK Bioscience Co ticker?

The ticker of SK Bioscience Co is 302440.KS.

How much dividend does SK Bioscience Co pay?

Over the past 12 months, SK Bioscience Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SK Bioscience Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of SK Bioscience Co?

The current dividend yield of SK Bioscience Co is .

When does SK Bioscience Co pay dividends?

SK Bioscience Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SK Bioscience Co?

SK Bioscience Co paid dividends every year for the past 0 years.

What is the dividend of SK Bioscience Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is SK Bioscience Co located?

SK Bioscience Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SK Bioscience Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SK Bioscience Co from 7/11/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.

When did SK Bioscience Co pay the last dividend?

The last dividend was paid out on 7/11/2024.

What was the dividend of SK Bioscience Co in the year 2023?

In the year 2023, SK Bioscience Co distributed 0 KRW as dividends.

In which currency does SK Bioscience Co pay out the dividend?

The dividends of SK Bioscience Co are distributed in KRW.

Other fundamentals and analyses of SK Bioscience Co in the deep dive.

Our stock analysis for SK Bioscience Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Bioscience Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.